Another monoclonal antibody-based imaging agent from Immunomedicshas been recommended for approval in Europe. The Morris Plains,NJ, company reported last week that its LeukoScan agent for imagingbone infection has received a positive recommendation from
Another monoclonal antibody-based imaging agent from Immunomedics
has been recommended for approval in Europe. The Morris Plains,
NJ, company reported last week that its LeukoScan agent for imaging
bone infection has received a positive recommendation from Europe's
Committee for Proprietary Medicinal Products. The company's CEA-Scan
product was cleared in Europe earlier this month (SCAN 10/9/96).
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.